Tasso Secures $17 Million Series A Financing to Scale Production of At-Home Blood Collection Systems and Capitalize on Growing Demand for Remote Diagnostic Testing
Jul 22, 2020•almost 5 years ago
Amount Raised
$17 Million
Round Type
series a
Description
Tasso Inc., a pioneer in clinical-grade, at-home, self-sampling blood collection, today announced it has completed an oversubscribed $17 million Series A financing round. The company will use the proceeds to scale manufacturing and operations to meet the increased demand for its line of innovative Tasso OnDemand devices, which enable people to collect their own blood using a virtually painless process from anywhere at any time. These fast and easy-to-use products are being adopted by leading academic medical institutions, government agencies, comprehensive cancer centers, and pharmaceutical organizations around the world.
FundzWatch™ Score
61
Medium Activity
Buyer Intent Analysis
Get personalized insights on buying likelihood
Funding Insights
Based on industry dataTech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech